HIGHLIGHTS
- who: Galam Leem and collaborators from the Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University have published the paper: Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial, in the Journal: Cancers 2022, 14, 4229. of /2022/
- what: Background and Aim: This study investigated the administration of combination therapy allogeneic natural killer (NK) cells and pembrolizumab the treatment of advanced biliary tract cancer to determine the safety and tolerability (phase 1) and the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.